27 completed. 27 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Completed 27 |
| Phase 2 | 4 | Completed 4 |
Follow Hereditary Angioedema: new trials by email Literature Review of Hereditary Angioedema trials Research Report on Hereditary Angioedema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II KVD900 150 mg, KVD900 300 mg, KVD900 600 mg - Hereditary Angioedema | Phase 3 | Completed | KalVista Pharmaceuticals, Ltd. | 36 | 2024-08-01 | 2026-08-05 |
| Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 3 | Completed | Pharvaris Netherlands B.V. | 134 | 2024-02-26 | 2025-11-21 |
| An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) KVD900 600 mg, KVD900 300 mg - Hereditary Angioedema | Phase 3 | Completed | KalVista Pharmaceuticals, Ltd. | 145 | 2022-10-24 | 2026-06-05 |
| PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial KVD900 600 mg, Drug: KVD900 300 mg - Hereditary Angioedema | Phase 3 | Completed | KalVista Pharmaceuticals, Ltd. | 11 | 2022-10-24 | 2026-06-08 |
| A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) Placebo, KVD900 600 mg, KVD900 300 mg - Hereditary Angioedema | Phase 3 | Completed | KalVista Pharmaceuticals, Ltd. | 136 | 2022-02-22 | 2025-05-02 |
| OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE) Donidalorsen, Placebo - Hereditary Angioedema | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 91 | 2021-12-03 | 2025-03-06 |
| Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks CSL312 - Hereditary Angioedema | Phase 3 | Completed | CSL Behring | 171 | 2021-03-29 | 2026-06-02 |
| Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema TAK-743 300 mg - Hereditary Angioedema | Phase 3 | Completed | Takeda | 12 | 2021-02-10 | 2023-06-26 |
| CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks CSL312, Placebo - Hereditary Angioedema | Phase 3 | Completed | CSL Behring | 64 | 2021-01-27 | 2023-06-29 |
| A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema TAK-667 - Hereditary Angioedema | Phase 3 | Completed | Takeda | 2 | 2021-01-15 | 2022-03-29 |
| A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children Lanadelumab - Hereditary Angioedema | Phase 3 | Completed | Shire | 21 | 2019-08-19 | 2022-05-26 |
| A Long Term Safety Study of BCX7353 in Hereditary Angioedema BCX7353 - Hereditary Angioedema, HAE | Phase 2 / Phase 3 | Completed | BioCryst Pharmaceuticals | 387 | 2018-02-16 | 2023-06-18 |
| Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE BCX7353 capsules, Placebo oral capsule - Hereditary Angioedema, HAE | Phase 3 | Completed | BioCryst Pharmaceuticals | 121 | 2018-02-06 | 2023-06-26 |
| 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks BCX4161, Placebo - Hereditary Angioedema, HAE | Phase 2 / Phase 3 | Completed | BioCryst Pharmaceuticals | 110 | 2014-12-17 | 2025-11-17 |
| Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks rhC1INH, Placebo (Saline) - Hereditary Angioedema | Phase 3 | Completed | Pharming Technologies B.V. | 75 | 2011-01-01 | 2015-08-07 |
| EASSI - Evaluation of the Safety of Self-Administration With Icatibant Icatibant - Hereditary Angioedema | Phase 3 | Completed | Shire | 151 | 2009-09-25 | 2021-06-11 |
| A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) Icatibant, Placebo - Hereditary Angioedema | Phase 3 | Completed | Shire | 98 | 2009-07-16 | 2021-06-11 |
| Berinert P Study of Subcutaneous Versus Intravenous Administration C1-Esterase Inhibitor - Hereditary Angioedema | Phase 3 | Completed | Johann Wolfgang Goethe University Hospital | 24 | 2008-09-01 | 2011-01-19 |
| Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks C1 esterase inhibitor [human] (C1INH-nf) - Hereditary Angioedema | Phase 3 | Completed | Shire | 113 | 2006-09-21 | 2021-06-08 |
| Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks C1 esterase inhibitor [human] (C1INH-nf) - Hereditary Angioedema | Phase 3 | Completed | Shire | 146 | 2006-06-27 | 2021-06-08 |
Showing 20 of 27. Sign in to see all of them.
Angioedemas, Hereditary (27) · Angioedema (3) · Genetic Diseases, Inborn (1) · Hereditary Angioedema Type III (1) · Hereditary Angioedema Types I and II (1)
Cardiovascular Diseases (27) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (27) · Hereditary Complement Deficiency Diseases (27) · Hypersensitivity (27) · Hypersensitivity, Immediate (27) · Immune System Diseases (27) · Immunologic Deficiency Syndromes (27) · Primary Immunodeficiency Diseases (27) · Skin Diseases (27) · Skin Diseases, Vascular (27) · Skin and Connective Tissue Diseases (27) · Urticaria (27) · Vascular Diseases (27) · Genetic Diseases, Inborn (26) · Angioedema (24)
Complement C1 Inhibitor Protein (9) · Sodium Chloride (5) · icatibant (4) · sebetralstat (4) · berotralstat (2) · conestat alfa (2) · lanadelumab (2) · Tranexamic Acid (1) · avoralstat (1) · donidalorsen (1)
Shire (8) · CSL Behring (4) · KalVista Pharmaceuticals, Ltd. (4) · BioCryst Pharmaceuticals (3) · Pharming Technologies B.V. (3) · Takeda (2) · Ionis Pharmaceuticals, Inc. (1) · Johann Wolfgang Goethe University Hospital (1) · Pharvaris Netherlands B.V. (1)
United States (20) · Canada (15) · Germany (14) · Hungary (12) · Israel (12) · Spain (11) · France (10) · Italy (10) · United Kingdom (10) · Japan (9) · Netherlands (9) · Romania (9) · Australia (8) · Bulgaria (7) · North Macedonia (7)
Anurag Relan, MD (1) · Bruce Zuraw, MD (1) · Henriette Farkas, MD (1) · Jan Nuijens, MD, PhD (1) · Marc Riedl, MD MS (1) · Wolfhart Kreuz, PD Phd (1)
PMID 36326435, PMID 20818886, PMID 23312695, PMID 42159953, PMID 20920772, PMID 22856635, PMID 23484892, PMID 23987198, PMID 28284978, PMID 36408587, PMID 40380356, PMID 40886933, PMID 42268494, PMID 17073887, PMID 19767078, PMID 20674826, PMID 20818888, PMID 21195947, PMID 21884533, PMID 22123383, PMID 22192966, PMID 22856636, PMID 22909164, PMID 23167682, PMID 23535096, PMID 24111645, PMID 24266596, PMID 24438203, PMID 25198193, PMID 25295804, PMID 26556097, PMID 33098856, PMID 33866032, PMID 34161665, PMID 35820771, PMID 36774155, PMID 36868261, PMID 37730089, PMID 38006972, PMID 38020288, PMID 38819395, PMID 40380363, PMID 40490218, PMID 41208217, PMID 41252457, PMID 42318595, PMID 42436759, PMID 42849489
2004 (2), 2008 (1), 2009 (1), 2018 (1)